Webinar Leaders

House Speaker

Emily Wilkinson, PhD
Research Analyst
Samuel Rabkin


 Samuel Rabkin, PhD Virologist – Massachusetts General Hospital

Guest Speaker

Angela Loskog, PhD Chief Executive Officer – Lokon Pharma AB

Guest Speaker

Paola Grandi, PhD Chief Scientific Officer – CG Oncology

Guest Speaker

Erik Wiklund Chief Business Officer – Targovax

About this webinar

  • An unparalleled understanding of oncolytic virotherapy drug development is seen from the eyes of Beacon from a landscape perspective and key players in the space. 
  • A closer look at the peaks and troughs of trends within the space highlights successes and challenges. 
  • Glean insight from experts in the science and commercial strategy to get oncolytic viruses from research to reality.  
  • The prime opportunity to ask the panel your questions on the space and what they think is the next step for oncolytic virotherapy development. 
Hosted by

In collaboration with
Massachusetts General Hospital Lokon Pharma AB Targovax CG Oncology

Speak with our team about Beacon Oncolytic Viruses

What is Beacon Oncolytic Viruses?





Beacon Oncolytic Viruses is a manually curated database solution that includes clinical trial and drug data for preclinical, active, approved, and discontinued virus-based therapies being developed for oncology indications. The database covers:

  • Genetically modified or naturally occurring virus-based therapies
  • Virus based therapeutics including viral-vaccines

Find out More

Our Oncolytic Viruses Team

Emily Wilkinson

Emily Wilkinson- Research Analyst

Gregory Kavalerov

Gregory Kavalerov – Account Manager

Contact Us

What is Beacon?

We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.

Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements

Find out more